In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 201 to 225 of 392

TitleTypeExpected publication date
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]Technology appraisal guidance
Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257Technology appraisal guidanceTBC
Maternal and child nutritionNICE guideline
Melanoma (metastatic) - talimogene laherparepvec [ID508]Technology appraisal guidance
Mental health guidelinesNICE guidelineTBC
Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442Technology appraisal guidanceTBC
Molnupiravir for treating COVID 19 [ID6340]Technology appraisal guidance
MRI-guided focused ultrasound subthalamotomy for treating Parkinson'sInterventional procedures guidance
MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson'sInterventional procedures guidance
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]Technology appraisal guidanceTBC
Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]Technology appraisal guidance
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]Technology appraisal guidanceTBC
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221Technology appraisal guidance
Nemolizumab for treating prurigo nodularis [ID6451]Technology appraisal guidance
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]Technology appraisal guidance
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]Technology appraisal guidanceTBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]Technology appraisal guidanceTBC
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Technology appraisal guidance
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]Technology appraisal guidanceTBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]Technology appraisal guidanceTBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All